Robbins LLP is reminding investors about a securities class action filed on behalf of purchasers of Ardelyx, Inc. common stock from January 13, 2025, through August 6, 2026. The complaint alleges Ardelyx misled investors about the commercial performance and growth prospects of IBSRELA and XPHOZAH while payer-related access and reimbursement barriers were becoming more restrictive. It says stricter prior authorization and step-edit requirements slowed new-patient starts and delayed prescription fulfillment. On August 6, 2026, Ardelyx reduced its full-year IBSRELA revenue guidance and withdrew long-term XPHOZAH revenue guidance, citing increased payer utilization-management processes and evolving market dynamics. The stock fell from $4.87 on August 6 to $4.00 on August 7, a decline of about 18%. Investors seeking appointment as lead plaintiff must contact Robbins LLP by November 16, 2026; appointment is not required to participate in any potential recovery, and the proposed class has not yet been certified.